Custom service
Peptide-siRNA Conjugation
Couple peptides to sirna strands for targeted knockdown studies
Peptide-siRNA Conjugation supports programmes that couple peptides to siRNA strands for targeted knockdown studies. In a typical engagement we plan the 3'-C6-maleimide oligonucleotide conjugation route first, confirm compatibility with GalNAc and CPP targeting ligands, and release purified siRNA conjugate under RNase-free QC on a 4–6 weeks schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep 3'-C6-maleimide oligonucleotide conjugation as the primary option and hold GalNAc and CPP targeting ligands in reserve, so that scale-up never depends on an unproven step.
GalNAc-driven hepatocyte delivery studies
Cell-targeted knockdown screening
Material intended for systemic in-vivo dosing
Conjugates whose payload cannot tolerate aqueous coupling conditions
Every conjugation batch is documented from vial to vial: carrier lot, payload lot, reagent lots, reaction conditions and purification chromatograms. The release package contains the loading ratio measured by an orthogonal method (UV, ICP-MS or amino-acid analysis), identity by mass spectrometry where the conjugate permits it, and residual-free-payload data.
Service Highlights
- 3'-C6-maleimide oligonucleotide conjugation as the default route, with GalNAc and CPP targeting ligands held as a proven fallback
- RNase-free handling workflow worked into the design where the application requires it
- Carrier and payload compatibility screened in a small feasibility batch before full material is committed
- Analytical confirmation of every intermediate before the final release
- Unreacted payload driven below the detection limit of the release assay before purification is closed
- Purified siRNA conjugate under RNase-free QC delivered with a complete conjugation or synthesis certificate
How the work runs
Scope & design
We review the payload, the carrier and the intended assay or study, and propose between 3'-C6-maleimide oligonucleotide conjugation and GalNAc and CPP targeting ligands as candidate routes.
Feasibility screen
A milligram-scale screen compares loading, residual payload and activity across the candidate conditions.
Production conjugation
The selected condition is executed at project scale with in-process sampling at fixed time points.
Purification
Size-exclusion, dialysis or magnetic separation removes free payload and by-products.
Characterization & release
Identity, loading ratio and functional activity are measured against the agreed specification.
Documentation & hand-off
Purified siRNA conjugate under RNase-free QC is packaged with the full batch record, released for shipment after QC sign-off.
Specifications & timeline
- Turnaround
- 4–6 weeks
- Typical scale
- 0.1–50 mg conjugate per batch
- Chemistry options
- 3'-C6-maleimide oligonucleotide conjugation; GalNAc and CPP targeting ligands; RNase-free handling workflow
- Deliverable
- Purified siRNA conjugate under RNase-free QC
- QC package
- HPLC/SEC trace, MALDI-TOF or ESI-MS, UV/Vis or ICP-MS loading ratio
- Shipping
- Blue ice or dry ice as the payload requires, with a cold-chain manifest
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.